Back to Clinical Trials
Phase 1Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Sponsored by Incyte Corporation

About this study

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Where this study is enrolling (2)

  • Mayo Clinic Hospital

    Phoenix, Arizona

    Call +1 480-342-2000

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Md Anderson Cancer Center

    Houston, Texas

    Call 877-632-6789

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓≥18 years old.
  • ✓Locally advanced or metastatic solid tumor with KRAS G12D mutation.
  • ✓For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
  • ✓Cohort specific requirements aas defined in the protocol.
  • ✓Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion criteria

  • ✕Prior treatment with any KRAS G12D inhibitor
  • ✕Known additional invasive malignancy within 1 year of the first dose of study drug
  • ✕History of organ transplant, including allogeneic stem cell transplantation
  • ✕Significant, uncontrolled medical condition
  • ✕History or presence of an ECG abnormality
  • ✕Inadequate organ function
  • ✕Other protocol-defined Inclusion/Exclusion Criteria may apply

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.